Posted inResearch
Clinical research company Javara lays off employees as part of restructuring
Clinical research firm Javara has laid off staff as part of a restructuring, a spokesperson confirmed to Fierce Biotech in…
Posted inBiotechnology
Applied Therapeutics CEO steps down in wake of FDA rejection, warning letter and investor lawsuit
A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D.,…
Posted inBiotechnology
Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to…
Posted inBiotechnology
Apollomics, after giving up on GlycoMimetics’ leukemia therapy, posts drug’s latest phase 3 fail
The failure of a myeloid leukemia drug in a phase 3 trial in China isn’t a shock to Apollomics, which…
Posted inBiotechnology
Novo Nordisk stock crashes after CagriSema misses phase 3 weight-loss goal
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss…
Posted inBiotechnology
Idorsia’s sale of Tryvio falls behind schedule, but layoffs remain on track
Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump, even as the biotech ploughs ahead with around…
Posted inBiotechnology
Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business
Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and…
Posted inGenetics
Mechanism for Cellular RNA’s Role in Antiviral Immune Response Uncovered
New research from scientists at the University of Washington (UW) School of Medicine and Duke University describes how cellular RNA…
Posted inGenetics
AI Expedites Motor Neuron Analysis and Screening in ALS Research
Developing motor neurons from stem cells taken directly from amyotrophic lateral sclerosis (ALS) patients offers new hope for better understanding…
Posted inBiotechnology
FDA rejects Zealand Pharma’s GLP-2 analog in rare bowel disease
The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel syndrome (SBS), citing…